Bathi sadurunge bunga, pajak, lan amortisasi: Lixte Biotechnology Holdings, Inc. (LIXT)
Lixte Biotechnology is developing innovative LB-100 phosphatase inhibitors to enhance chemotherapy by investing in scientific potential. This chart, provided by the GURU.Markets platform, shows that EBITDA reached 0.00. Management is aggressively raising capital to achieve medical breakthroughs, while a compact staff of biochemists leverages strong ties with academic centers.
Ringkesan rincian data analitis Lixte Biotechnology Holdings, Inc. (LIXT)
- kuotasi lan prakiraan analis:
- indikator kapitalisasi bursa perusahaan:
- data kapitalisasi buku:
- data tingkat utang lan likuiditas finansial:
Utang marang Modal Lixte Biotechnology|LIXT - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Lixte Biotechnology Holdings Inc.|LIXT - Utang perusahaan|Utang-utang marang nilai buku Lixte Biotechnology|LIXT - Utang jangka dawa perusahaan|Tanggungan jangka cendhak Lixte Biotechnology|Likuiditas darurat lixte.com
- indikator bathi lan kelipatan valuasi:
LIXT - Penghasilan resik|Penghasilan resik sing dikarepake Lixte Biotechnology|LIXT - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep lixte.com|LIXT - Pangali PEG|Nilai bisnis marang bathi operasional sadurunge panyusutan Lixte Biotechnology|LIXT - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Lixte Biotechnology|LIXT - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan lixte.com|LIXT - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Lixte Biotechnology
Analisis kabeh metrik perusahaan:Lixte Biotechnology
This indicator reflects net cash flow from operating activities before depreciation and interest, allowing for an assessment of the business's actual scalability without accounting adjustments. By analyzing EBITDA in cash terms, an investor can see how the automation of protein inhibitor discovery via AI modeling converts into operational efficiency, confirming the viability of the digital strategy of Lixte Biotechnology (LIXT).
Karo sapa Lixte Biotechnology saingan
Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi INCY|HCM - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi sadurunge bunga, pajak, lan amortisasi nuvationbio.com|Day One Biopharmaceuticals (DAWN) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi operasional sadurunge amortisasi MNPR|INBX (Inhibrx Biosciences Inc) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi I-Mab Inc. (IMAB)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Fennec Pharmaceuticals (FENC)|HRTX - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Nuvectis Pharma NVCT|Coherus - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|CRBP - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi sadurunge bunga, pajak, lan amortisasi Cardiff Oncology, Inc.|BYSI: Bathi operasional EBITDA|Bathi operasional sadurunge potongan amortisasi BioAtla BCAB|Bathi operasional sadurunge ngurangi amortisasi CTXR|Bathi sadurunge bunga, pajak, lan amortisasi Cellectar Biosciences Inc CLRB|Bathi operasional sadurunge ngurangi amortisasi BLRX (BioLineRx Corp)|CANF (Can-Fite) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Aprea Therapeutics, Inc. - Bathi operasional sadurunge ngurangi amortisasi|Bathi perusahaan sadurunge pajak, bunga, lan amortisasi KZIA (Kazia Therapeutics Ltd)|Silexion - Bathi operasional EBITDA|Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi NCNA (NuCana plc)|CMRX: Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi Cyclacel, Inc. (CYCC)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi G1 Therapeutics Inc.|KRON: Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi operasional EBITDA KTRA|Bathi operasional EBITDA Oncternal Therapeutics Inc (ONCT)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Portage PRTG
